Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
Archives of Disease in Childhood
|
April 16, 2024
3D printing: a useful tool for safe clinical practice in children with complex vasculature
Alicia Paessler, Colin Forman, Kishore Minhas, et al.
The Lancet. Oncology
|
August 25, 2011
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, et al.
Transactions. Edinburgh Obstetrical Society
|
April 4, 2018
Discussion-Should Midwives Be Registered in Scotland?
Berry Hart, A H F Barbour, R C Buist, et al.
The New England Journal of Medicine
|
March 29, 2012
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
Jonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
Parasites & Vectors
|
November 8, 2014
Establishment of macrocyclic lactone resistant Dirofilaria immitis isolates in experimentally infected laboratory dogs
Cassan N Pulaski, John B Malone, Catherine Bourguinat, et al.
Lancet (London, England)
|
July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt, Mark Robson, Judy E Garber, et al.
Lancet (London, England)
|
July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M William Audeh, James Carmichael, Richard T Penson, et al.
Seminars in Oncology
|
February 19, 2005
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials
David S Alberts, Franco M Muggia, James Carmichael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
Martine J Piccart-Gebhart, Tomasz Burzykowski, Marc Buyse, et al.
Elife
|
September 21, 2018
UBE2G1 governs the destruction of cereblon neomorphic substrates
Gang Lu, Stephanie Weng, Mary Matyskiela, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
Archives of Disease in Childhood
|
April 16, 2024
3D printing: a useful tool for safe clinical practice in children with complex vasculature
Alicia Paessler, Colin Forman, Kishore Minhas, et al.
The Lancet. Oncology
|
August 25, 2011
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, et al.
Transactions. Edinburgh Obstetrical Society
|
April 4, 2018
Discussion-Should Midwives Be Registered in Scotland?
Berry Hart, A H F Barbour, R C Buist, et al.
The New England Journal of Medicine
|
March 29, 2012
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
Jonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
Parasites & Vectors
|
November 8, 2014
Establishment of macrocyclic lactone resistant Dirofilaria immitis isolates in experimentally infected laboratory dogs
Cassan N Pulaski, John B Malone, Catherine Bourguinat, et al.
Lancet (London, England)
|
July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt, Mark Robson, Judy E Garber, et al.
Lancet (London, England)
|
July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M William Audeh, James Carmichael, Richard T Penson, et al.
Seminars in Oncology
|
February 19, 2005
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials
David S Alberts, Franco M Muggia, James Carmichael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
Martine J Piccart-Gebhart, Tomasz Burzykowski, Marc Buyse, et al.
Elife
|
September 21, 2018
UBE2G1 governs the destruction of cereblon neomorphic substrates
Gang Lu, Stephanie Weng, Mary Matyskiela, et al.
Page
of 7